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Abstract
Objective: Postmortem studies reported significant microglia activation in
association with neuronal apoptosis in Fatal Familial Insomnia (FFI), indicating
a specific glial response, but negative evidence also exists. An in vivo study of
local immune responses over FFI natural course may contribute to the under-
standing of the underlying pathogenesis. Methods: We included eight presymp-
tomatic subjects (mean  SD age:44.13  3.83 years) carrying the pathogenic
D178N-129met FFI mutation, one symptomatic patient (male, 45 yrs. old), and
nine healthy controls (HC) (mean  SD age: 44.00  11.10 years.) for com-
parisons. 11C-(R)-PK11195 PET allowed the measurement of Translocator Pro-
tein (TSPO) overexpression, indexing microglia activation. A clustering
algorithm was adopted to define subject-specific reference regions. Voxel-wise
statistical analyses were performed on 11C-(R)-PK11195 binding potential (BP)
images both at the group and individual level. Results: The D178N-129met/val
FFI patient showed significant 11C-(R)-PK11195 BP increases in the midbrain,
cerebellum, anterior thalamus, anterior cingulate cortex, orbitofrontal cortex,
and anterior insula, bilaterally. Similar TSPO increases, but limited to limbic
structures, were observed in four out of eight presymptomatic carriers. The
only carrier with the codon 129met/val polymorphism was the only one showing
an additional TSPO increase in the anterior thalamus. Interpretation: In com-
parison to nonprion neurodegenerative diseases, the observed lack of a diffuse
brain TSPO overexpression in preclinical and the clinical FFI cases suggests the
presence of a different microglia response. The involvement of limbic structures
might indicate a role for microglia activation in these key pathologic regions,
known to show the most significant neuronal loss and functional
deafferentation in FFI.
Introduction
Prion Diseases (PrDs) or transmissible spongiform ence-
phalopathies (TSEs) are a group of rapidly progressive
conditions characterized by the accumulation of mis-
folded prion protein (scrapie PrP - PrPSc).1 Human prion
diseases include conditions such as Creutzfeldt–Jakob Dis-
ease (CJD) and Fatal Familial Insomnia (FFI) and include
sporadic, genetic, and acquired forms.2,3
The net majority of the fatal insomnia cases are famil-
ial, with FFI qualifying as one of the most common
inherited prion disease worldwide.3 FFI is a rare disease4
linked to a missense mutation in the prion protein gene
(PRNP) at codon-178, with aspartate-asparagine replace-
ment (Asp?Asn) (D178N mutation),5,6 which has a high,
almost complete, penetrance.5–7 The D178N mutation can
trigger different clinico-pathological syndromes, either
thalamic-dominant FFI or CJD, depending on a
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methionine-valine polymorphism at PRNP codon-129.8–10
FFI syndrome is almost exclusively associated with
methionine in the mutated allele (D178N-129M),9 but
not all the carriers of the D178N-129M mutation develop
an FFI phenotype.11,12 Additionally, methionine/valine
polymorphism in the normal allele appears relevant for
disease progression and severity, with FFI D178N-129M/M
patients presenting with a more rapid decline compared
to D178N-129M/V cases.9 FFI presents with disrupted
sleep (loss of sleep spindles and slow-wave sleep and
enacted dreams), autonomic hyperactivation and motor
abnormalities (myoclonus, ataxia, dysarthria, dysphagia,
and pyramidal signs).13,14
Postmortem tissue evaluation consistently reveals neu-
ronal death due to apoptosis and gliosis, largely confined to
the ventral anterior and dorso-medial thalamic nuclei and
inferior olivary nuclei, not correlating with the amount of
PrPSc deposition.10,13,15–17 Previous studies have reported
only mild PrPSc accumulation in FFI, particularly in
patients with the shortest disease duration.16,18 Significant
microglia activation has been described in association with
neuronal apoptosis in FFI, both in terms of topography
and magnitude,17 but negative evidence also exists.19,20
Structural Magnetic Resonance Imaging (MRI) studies
have provided negative/heterogeneous evidence for vol-
ume loss,21 whereas novel approaches with diffusion ten-
sor imaging (DTI) revealed significant alterations in the
thalamus, cerebellum, and medulla oblongata.22,23
With regard to molecular Positron Emission Tomogra-
phy (PET) imaging, several18F-FDG-PET studies revealed
focal thalamic hypometabolism in FFI, variably reaching
limbic and frontotemporal cortical regions possibly due
to thalamic functional deafferentation.18,21,24,25 Limbic
and cortical involvement is also supported by pathology
studies showing a spread of PrPSc deposition, neurode-
generation, and gliosis in these areas, depending on dis-
ease duration.8,18
To date, the relationships between PrPSc, neuronal
apoptosis, spongiform change, and brain immune activa-
tion are not yet fully understood.17 In contrast to some
in vivo26 and postmortem evidence in CJD,27 the in vivo
dynamics of microglia responses in FFI are currently
unknown.17,20
PET with specific radioligands, such as the carbon-11
labeled (R)-PK11195, allows the in vivo investigation of
microglia activation in humans.28 These techniques detect
overexpression of the 18 kDa Translocator Protein
(TSPO), an outer mitochondrial membrane protein
whose levels rise during microglia activation29 but also, to
a lesser extent, during astrocytes and macrophage activa-
tion.29,30 This technique has been previously adopted in
several neurodegenerative conditions,28,31 including prion
diseases.26
Here, we employed 11C-(R)-PK11195-PET to evaluate
presence and temporal course of microglia activation,
in vivo, in both presymptomatic carriers of the FFI




We enrolled eight presymptomatic carriers of the D178N
PRNP mutation (age mean  SD 44.13  3.83 years),
belonging to three Italian families. Seven of them (FFI
Carriers 1-7) were homozygous, 129M/M, whereas only
one (FFI Carrier 8) was heterozygous, 129M/V, at PRNP
codon 129. All the 11C-(R)-PK11195 scans were per-
formed at the Nuclear Medicine Unit of the San Raffaele
Hospital (Milan, Italy) between 2006 and 2008. Of note,
all the carriers are currently still asymptomatic (June
2017). The only FFI patient was a male, 45 years old,
who carried a 129met/val polymorphism. He was evaluated
6 months after symptom onset and was still autonomous
at the time of PET. He died 8 months after PET, thus
presenting with a total 14 months of disease duration
(see Table 1, sensitive data, such as sex and age, is not
revealed for confidentiality reasons).
11C-(R)-PK11195 PET scans of nine healthy volunteers
were included for comparison (mean age  SD:
44.00  11.10). The controls were external volunteers
(N = 6) or relatives of the presymptomatic carriers with-
out the mutation (N = 3).
All the procedures involving human participants per-
formed in this study were in accordance with the ethical
standards of the institutional and/or national research
committee and with the 1964 Helsinki declaration and its
later amendments or comparable ethical standards. All
Table 1. Summary of the FFI cohort.
ID PRNP codon 129 Follow-up (years) PET–Study time
FFI Patient met/val –
FFI Carrier 1 met/met 11
FFI Carrier 2 met/met 10
FFI Carrier 3 met/met 11
FFI Carrier 4 met/met 10
FFI Carrier 5 met/met 10
FFI Carrier 6 met/met 11
FFI Carrier 7 met/met 11
FFI Carrier 8 met/val 9
FFI, Fatal Familial Insomnia; PRNP, Prion Protein Gene; met, methion-
ine; val, valine.
Sensitive data, such as sex and age, is not revealed for confidentiality
reasons.
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the subjects involved personally gave their informed
consent.
11C-(R)-PK11195 PET acquisition
11C-(R)-PK11195 PET scans were performed at the
Nuclear Medicine Unit of San Raffaele Hospital (Milan,
Italy), with multi-ring PET tomographs, either PET-CT
system “Discovery LS” or “Discovery 690” General Elec-
tric Medical Systems. 11C-(R)-PK11195 injected dose was
of approximately 370  37 MBq, with optimal radio-
chemical and chemical purity >95%.32
The acquisition protocol consisted of a dynamic scan of
15 frames with a total duration of 58 min, that is,
6 x 30 sec/ 2 x 1 m/1 x 3 m/3 x 5 m/2 x 10 m/1 x 15 m.
PET data were corrected for attenuation artifacts, radioac-
tive decay, and scatter. Transaxial images were recon-
structed using a Shepp-Logan filter (cut-off 5 mm filter
width) in the transaxial plane, and a Shepp-Logan filter
(cut-off 8.5 mm) in the axial direction. For each scan, the
individual frames were realigned over time with statistical
parametric mapping (SPM5) software to account for move-
ment during acquisition.
11C-(R)-PK11195 PET data processing
11C-(R)-PK11195 nondisplaceable binding potential
(BPND) images were estimated with a Receptor Parametric
Mapping (RPM) (0.04 min1 lower bound, 1.0 min1
upper bound, 30 basis functions)33 procedure, a basis
function implementation of the Simplified Reference Tis-
sue Modeling (SRTM) method.34 The SRTM analysis gen-
erates BPs by modeling the time activity curve (TAC) of
a preset reference region and comparing it voxel-wise in
the whole scan.34 The identification of a reference region
with 11C-(R)-PK11195-PET can be particularly challeng-
ing, since the delivery of the tracer is homogeneous across
the whole-brain, hindering the delineation of an anatomi-
cally defined region.35,36 This methodological caveat led
to the development of automated clustering algorithms
able to select pseudo-reference regions, that is, clusters of
voxels sharing a specific TAC.35,37 Here, we employed the
Curve Distance Clustering Algorithm (CDCA),38 which is
an adaptation of the well-validated SuperVised Clustering
Algorithm.35
The CDCA algorithm estimates the similarity of the
TACs of each voxel with four predefined TACs, represent-
ing reference tracer delivery in four compartments, that
is, blood, white matter, gray matter with nonspecific
binding and high-specific binding.38 The voxels with a
TAC most resembling of the gray matter with nonspecific
binding compartment were then used as reference region
for the parametric BP analysis.
The clustering maps obtained with the CDCA procedure
were also used to spatially normalize 11C-(R)-PK11195 BP
images to the standard Montreal Neurological Institute
(MNI) space. The probability maps of the gray and white
matter were entered into the unified segmentation module
of SPM12. The resulting spatial transformations were used
for the warping to MNI space and to subsequently deform
a standardized MNI mask to native space in order to mask
extracranial uptake. This pipeline resulted in masked and
warped 11C-(R)-PK11195 BP images.
11C-(R)-PK11195 PET analysis
Voxel-wise statistical comparisons in the FFI carriers were
performed at group and single-subject levels. Analyses were
run with SPM12 software, covarying for age as a nuisance
factor. Statistical significance was set at P < 0.001 (uncor-
rected for multiple comparisons), with minimum cluster
extent k:100 voxels. Single-subject analysis was performed
by estimating individual voxel-wise z-score maps for the
symptomatic patient and FFI mutation carriers using the
mean and standard deviation of 11C-(R)-PK11195 values in
the healthy controls. Consistent with the group compar-




The group analysis showed no statistically significant dif-
ferences with the healthy controls. At single- subject eval-
uation, clusters of significant activation were present in
limbic regions in four FFI presymptomatic carriers (carri-
ers 1,3,6,8), namely the insula and the cingulate cortex in
all the subjects; other than in the putamen and pallidum
in carriers 1 and 3, respectively (see Fig. 1). Of note, car-
rier 8 was the only D178N-129M/V and also the only
showing significant focal 11C-(R)-PK11195 BP increases
in the left anterior thalamus, comparable to the FFI
D178N-129M/V patient pattern (see below and Fig. 1).
The lack of thalamic involvement was confirmed in all
the other carriers also adopting more liberal statistical
thresholds, that is, z > 2.58 (two-sided, P < 0.01).
FFI symptomatic patient
The single-subject analysis revealed significant cortical
TSPO overexpression, peaking in the anterior cingulate
cortex, in the medial orbitofrontal cortex and in the ante-
rior insula. At the subcortical level, the FFI patient
showed confined and significant BP increases in the ante-
rior thalamus (MNI 14,4,8), with a remarkable
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colocalization observed in FFI carrier 8. The closest fit to
atlas-based subnuclei was with the ventral thalamic ante-
rior nuclei. Of note, the FFI patient additionally showed
significant focal 11C-(R)-PK11195 increases in the left
midbrain (MNI 10, 20, 5) and cerebellum (MNI 14,
52, 32; 38, 66, 48; 12, 51, 56) (see Fig. 1).
Discussion
FFI is a fatal monogenic disease characterized by a speci-
fic combination of a missense mutation and an in cis sin-
gle-nucleotide polymorphism in the PRNP gene.39 The
D178N-129M combination predominantly yields a unique
clinical and neuropathological signature, with selective
thalamic and brainstem nuclei degeneration leading to a
fatal disease characterized by severe sleep alterations with
autonomic hyperactivity and myoclonus.15,39 Here, we
present the first in vivo 11C-(R)-PK11195 PET study of
microglia activation in presymptomatic carriers of the
Fatal Familial Insomnia PRNP D178N-129M pathogenic
mutation, and an evaluation in a single symptomatic
patient.
Ever since its characterization,5,6,13 FFI has consistently
shown remarkably distinct clinical and pathological fea-
tures, defining a unique entity within prionopathies.8 One
cardinal difference with other prionopathies relates to the
Figure 1. 11C-(R)-PK11195 BP increases in single subjects. Figure shows significant (z > 2.58, P < 0.01 two-tailed) 11C-(R)-PK11195 BP elevation
in four carriers, three D178N-129met/met and one D178N-129met/val, together with the symptomatic patient (D178N-129met/val). Red circles
highlight BP increases in the anterior thalamic nuclei in Carrier 8 and the patient. Voxels with significant increases are overlaid on a standard
anatomical template with MRIcron software on multiple axial and sagittal slices (http://www.mccauslandcenter.sc.edu/crnl/tools). BP, binding
potential.
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generally low accumulation of PrPSc aggregates, reaching
significant levels only in the cerebral cortex of the cases
with the longest disease duration.3,8
The association between microglial activation and the
neuropathological changes in FFI remains elusive, high-
lighted by the discordant results provided by autopsy stud-
ies.17,19,20 Postmortem evidence indeed showed significant
microglia activation in FFI, with a remarkable concordance
with neuronal apoptosis, both in terms of topography and
magnitude.17,20 It was then suggested that in FFI, microglia
cells could reactively migrate to apoptotic sites to digest
debris or, conversely, could somehow fuel neuronal apop-
tosis through the activation of pro-inflammatory signaling
cascades.17,40 Still, there is evidence for a lack of association
between microglia activation in FFI and interleukin-1b
levels, thus not supporting the latter hypothesis.17
The present unique in vivo PET findings in D178N-
129M/M pre-symptomatic mutation carriers crucially show
a lack of significant in vivo TSPO overexpression (i.e.,
microglia activation) in key FFI pathology regions, that is,
ventral anterior and medial dorsal thalamic nuclei and infe-
rior olivary nuclei. The here included presymptomatic car-
riers were on average about 44 years old and were still
asymptomatic (June 2017), after an average 10 years of fol-
low-up after PET scan. Considering that FFI has been
shown to harbor almost complete penetrance,7 with risk of
clinical onset peaking around 50–55 years of age,41 our
cohort was studied about 6–11 years before the expected
clinical onset. These negative 11C-(R)-PK11195-PET find-
ings are in accordance with a previous 18F-FDG-PET study
in FFI presymptomatic mutation carriers, showing the only
dysfunctional marker being significant thalamic hypometa-
bolism.42 More specifically, the latter was evident only
shortly before the clinical onset (about 13–21 months)42
and was considered related to underlying fast and abrupt
pathology processes. Four out of eight presymptomatic car-
riers showed spatially consistent and significant 11C-(R)-
PK11195 BP increases in the limbic structures, such as
anterior/middle/posterior cingulate cortices and insula;
with two of them showing an additional involvement of
basal ganglia. Unraveling the biological meaning of these
brain 11C-(R)-PK11195 BP increases in presymptomatic
carriers is challenging. All the carriers were neurologically
normal and did not have any clinical complaint. Consider-
ing the asymptomatic phase and the previous in vivo evi-
dence, both the presence of PrPSc pathology and
neurodegeneration are unlikely. This is confirmed by the
lack of significant increases in regions where the pathogenic
process is expected to begin, that is, medulla oblongata and
anterior ventral/dorso-medial thalamic nuclei, in all carri-
ers but one (see below). The observed pattern of microglia
activation could be due to molecular mechanisms that are
in need of further studies. Therefore, while the present data
provide some evidence for limbic microglial activation in
presymptomatic FFI, these results should be interpreted
with caution.
Notably, the symptomatic FFI patient showed signifi-
cant 11C-(R)-PK11195 BP increases in key FFI pathology
regions, such as the ventral anterior thalamic nuclei, the
midbrain and the cerebellum. It is of particular interest
that the only presymptomatic carrier with a codon 129M/V
polymorphism showed a rather limited but significant
TSPO overexpression in anterior thalamus, orbitofrontal
cortex, and right anterior insula, all topographically con-
sistent with the pattern seen in the affected patient.
While it is tempting to speculate that the codon 129
polymorphism could be associated with differential
dynamics of microglia responses in FFI, the present find-
ings cannot unequivocally confirm this claim and further
studies are needed.
These findings suggest that, although confined, FFI in
the symptomatic phase may be associated with a selective
and focal microglia activation in key pathologic subcorti-
cal regions, extending to limbic cortical regions perhaps
bearing functional deafferentation effects. At the cortical
levels, previously reported FFI patients with longer disease
durations (i.e., D178N-129M/V) showed both marked
in vivo 18F-FDG-PET hypometabolism and significant
postmortem spongiosis and gliosis, with a milder neu-
ronal loss especially evident in frontal and cingulate
regions.18,24,39
We have recently described significant 11C-(R)-
PK11195 BP increases in CJD, with magnitude and
topography varying according to the clinical subtype.26 In
particular, more significant increases were observed at the
subcortical levels in variant CJD and cortical levels in typ-
ical sporadic CJD, whereas the only genetic CJD patient
(PRNP V210I mutation) showed the most confined and
least significant increases.26 Both the genetic V210I CJD
and the D178N-129M/V FFI showed an overall lower mag-
nitude of in vivo 11C-(R)-PK11195 BP increases, in com-
parison to the sporadic and the variant CJD cases.26 It is
tempting to speculate that these genetic prion disease
cases could have been characterized by a slowly progres-
sive incubation period, reflecting in a distinctive temporal
dynamic of microglia activation. This would imply that,
in preclinical and earliest clinical phases of genetic prion
diseases, microglia cells could be not activated or, alterna-
tively, activated in a neuroprotective phenotype. With dis-
ease progression and chronicity of pathology
accumulation, microglia cells could progressively activate
and switch to a more aggressive functional phenotype,
possibly detected by 11C-(R)-PK11195-PET (see below).
Genetic prion diseases have been classified as “fast” or
“slow” based on the usual clinical course, ranging from
very rapid (<3 years of disease duration) to slower
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courses (>3 years), witnessing a pronounced variability
concerning survival time.4 Therefore, this hypothesis is
more likely to hold true in slower, less fulminant, genetic
cases.
Very few previous studies have evaluated in vivo TSPO
overexpression in presymptomatic mutation carriers of
neurodegenerative proteinopathies, and crucially none of
them in prion diseases. Significant striatal and cortical
11C-(R)-PK11195 binding increases have been described
in premanifest Huntington Disease (HD) mutation carri-
ers, also correlating with the short-time probability of dis-
ease onset.43 Another study employing 11C-DAA1006-PET
found significant TSPO overexpression in presymptomatic
genetic carriers of microtubule-associated protein tau
(MAPT) mutation.44
Neuroinflammation has been evaluated also by means
of 11C-deuterium-L-deprenyl, indexing brain astrocytosis,
in a study addressing presymptomatic carriers of inherited
autosomal dominant AD (ADAD).45 Of note, brain astro-
cytosis in ADAD is higher in the presymptomatic phases
of disease, and steadily declines approaching clinical
onset.45 It is reasonable to consider that neurodegenera-
tive conditions with long-lasting pathology accumulation,
progressive insidious clinical onset, and longer survival
time, such as genetic AD, are characterized by different
microglial characteristics and temporal dynamics when
compared to conditions with an abrupt clinical onset and
short survival times, for example, in prion disease.
The present findings should also be considered in light
of the lacking consensus on whether TSPO-based PET
radioligands preferentially detect specific microglia func-
tional states. Microglia are extremely versatile cells, which
can acquire diverse phenotypes in response to specific
trigger insults.46 In postmortem evidence in pri-
onopathies, microglia cells seem to be able to clear apop-
totic material but not PrPSc, even after priming with
lipopolysaccharide stimulation.47 Apoptosis is the leading
neuronal death mechanism in FFI17 and is known to trig-
ger a specific neuroprotective microglial response, ori-
ented toward phagocytosis of debris and restoration of
tissue homeostasis through anti-inflammatory signal-
ing.47,48 It is conceivable that at some point, the unremit-
ting accumulation of PrPSc pathology, together with
increased neuronal loss, ultimately triggers a microglial
functional switch, that is, from neuroprotective to neuro-
toxic, which has already been suggested in prion dis-
eases.27 In FFI, thalamus, midbrain, brainstem, and
cerebellum bear the brunt of pathology8,15 and here we
showed focal and significant in vivo TSPO overexpression
in the symptomatic patient. FFI patients with longest dis-
ease course have shown cortical pathology and dysfunc-
tion18,24 and we here consistently detected TSPO
overexpression in cortical regions in vivo.
Thus, microglia activation seems to be part of the FFI
pathology, in a peculiar and/or limited amount. Whether
specific microglia functional states are present early in the
FFI course, switching to the harmful aggressive phenotype
in later phases, is a crucial issue in need of further stud-
ies, also considering the development of possible
immunomodulatory interventions.
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